ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1215

Filgotinib Provided Rapid and Sustained Relief of Pain and Fatigue and Improved Health-Related Quality of Life in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs

David Walker1, Tsutomu Takeuchi2, Beatrix Bartok3, Shangbang Rao3, I-Heng Lee4, Robin Besuyen5, Jacques-Eric Gottenberg6 and Mark Genovese3, 1Northumbria Healthcare Trust, North Shields, United Kingdom, 2Keio Univ School of Medicine, Tokyo, Japan, 3Gilead Sciences, Inc., Foster City, CA, 4Gilead Sciences, Foster City, CA, 5Galapagos BV, Leiden, Netherlands, 6Strasbourg University Hospital, Strasbourg, France

Meeting: ACR Convergence 2020

Keywords: Fatigue, pain, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: EULAR guidelines recommend a treat-to-target approach focusing on reducing inflammation to prevent joint damage, physical disability, and mortality.1 However, patients consider reduction in pain and fatigue, along with maintenance of physical function, and improvement in health-related quality of life (HRQoL) important areas for improvement with RA treatment.2 In the FINCH 2 study, filgotinib (FIL)—a potent, selective, oral small molecule Janus kinase 1 inhibitor—in combination with conventional synthetic (cs)DMARD therapy significantly improved the signs and symptoms of rheumatoid arthritis (RA) in patients with an inadequate response to a biologic (b)DMARD compared with placebo (PBO).3  In addition, patients experienced significant improvements in HAQ-DI at week (W)12 and W24 with FIL 100 mg (p < 0.001, p = 0.003) or 200 mg (p < 0.001 for both) compared with PBO.3 The rate and magnitude of change in patient-reported outcomes (PROs) from FINCH 2 assessing pain, HRQoL and fatigue were evaluated.

Methods: Patients in this double-blind, randomized study (NCT02873936) received FIL 200 mg, FIL 100 mg, or PBO while continuing csDMARD therapy. PROs were collected prospectively on day 1 and at the W2, W4, W8, W12, W14, W16, W20, and W24 visits for assessment of pain (VAS pain scale]) and on day 1 and at W4, W12, and W24 for assessment of fatigue (FACIT-Fatigue) and HRQoL (SF-36). Changes from baseline for each PRO at each time point up to W24 were analyzed longitudinally using a mixed-effects model for repeated measures. P values for the difference between each FIL arm and PBO at each time point were calculated.

Results: Among the 448 patients randomized and treated (FIL 200 mg, n = 147; FIL 100 mg, n = 153; PBO, n = 148) 381 (85.0%) completed the study. Baseline mean (SD) VAS pain scale was 67 (21.0), SF-36 physical component summary (PCS) was 31.1 (7.89), SF-36 mental component summary (MCS) was 44.3 (11.6), and FACIT-Fatigue score was 24.4 (11.6); baseline values did not vary between treatment groups. Significantly greater improvements in VAS pain scores began at W2 and were maintained through W24 for patients who received either dose of FIL vs PBO (Fig 1A). FIL also significantly improved patients’ fatigue at W4, W12, and W24 compared with PBO for those receiving 200 mg doses, and at W4 and W12 for those receiving 100 mg doses (Fig 1B). HRQoL related to physical functioning (SF-36 PCS) was significantly enhanced at W4, W12, and W24 with both doses of FIL as compared with PBO (Fig 2A). Improvements to mental-health-related QoL (SF-36 MCS) were reported for FIL as early as W4 and maintained through W24, with statistically significant improvements at W4 and W12 for FIL 200 mg vs PBO (Fig 2B).

Conclusion: In a patient population with refractory disease that had inadequate response to prior bDMARDs and had significant disease at baseline, FIL treatment—coadministered with csDMARD therapy—was able to provide rapid and sustained improvements in key measures of pain, HRQoL, and fatigue as reported by patients. 

References:

1) Smolen, et al. Ann Rheum Dis. 2017;76:960–77.
2) Fautrel, et al. Rheumatol Int. 2018;38:935–47.
3) Genovese, et al. JAMA. 2019;322(4):315–25.


Disclosure: D. Walker, Gilead, 2, 5, Lilly, 5, 8, Pfizer, 5, 8, Novartis, 5, 8; T. Takeuchi, AbbVie, 2, 8, Asahikasei Pharma Corp., 2, 5, Astellas Pharma, Inc., 2, 5, AYUMI Pharmaceutical Corp., 8, Bristol-Myers Squibb, 8, Chugai Pharmaceutical Co, Ltd., 2, 5, 8, Daiichi Sankyo Co., Ltd., 2, 8, Eisai Co., Ltd., 2, 8, Eli Lilly Japan,, 5, 8, Gilead Sciences, Inc., 8, Mitsubishi-Tanabe Pharma Corp., 2, 8, Nipponkayaku Co.Ltd., 2, Novartis Pharma K.K., 8, Pfizer Japan Inc., 8, Sanofi K.K., 8, Shionogi & Co., Ltd., 2, Takeda Pharmaceutical Co., Ltd., 2, UCB Japan, 2, Dainippon Sumitomo Co., Ltd., 8; B. Bartok, Gilead Sciences, Inc., 1, 3; S. Rao, Gilead Sciences, Inc., 1, 3; I. Lee, Gilead Sciences, 1, 2; R. Besuyen, Galapagos, 1, 3; J. Gottenberg, Bristol-Myers Squibb, 2, 8, Pfizer, 2, 5, UCB, 5, 8, Eli Lilly, 2, 8, AbbVie, 2, 8, Roche, 2, 8, Sanofi-Genzyme, 5, 8; M. Genovese, AbbVie, 2, 5, Eli Lily and Co, 2, 5, EMD Merck Serono, 2, 5, Galapagos, 2, Genentech/Roche, 2, 5, Gilead Sciences, Inc., 1, 2, 3, 5, GSK, 2, 5, Novartis, 2, 5, Pfizer, Inc., 2, Rpharm, 2, 5, Sanofi Genzyme, 2, 5.

To cite this abstract in AMA style:

Walker D, Takeuchi T, Bartok B, Rao S, Lee I, Besuyen R, Gottenberg J, Genovese M. Filgotinib Provided Rapid and Sustained Relief of Pain and Fatigue and Improved Health-Related Quality of Life in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/filgotinib-provided-rapid-and-sustained-relief-of-pain-and-fatigue-and-improved-health-related-quality-of-life-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-biologic-dmards/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/filgotinib-provided-rapid-and-sustained-relief-of-pain-and-fatigue-and-improved-health-related-quality-of-life-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-biologic-dmards/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology